Recursion Pharmaceuticals Dirección
Dirección controles de criterios 1/4
El CEO de Recursion Pharmaceuticals es Najat Khan , nombrado en Jan 2026, tiene una permanencia de menos de un año. compensación anual total es $9.19M, compuesta por 3.1% salario y 96.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.008% de las acciones de la empresa, por valor de $137.24K. La antigüedad media del equipo directivo y de la junta directiva es de 1.5 años y 10.6 años, respectivamente.
Información clave
Najat Khan
Chief Executive Officer (CEO)
US$9.2m
Compensación total
| Porcentaje del salario del CEO | 3.10% |
| Permanencia del CEO | less than a year |
| Participación del CEO | 0.008% |
| Permanencia media de la dirección | 1.5yrs |
| Promedio de permanencia en la Junta Directiva | 10.6yrs |
Actualizaciones recientes de la dirección
Recent updates
News Flash: 9 Analysts Think Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Earnings Are Under Threat
May 04
Recursion Pharmaceuticals! WTH is going on?
Recursion Pharmaceuticals (RXRX) one day will be the Palantir of biotechnology! With the CMO transitioning out as well as the former CEO RXRX now has a chance to take off!Recursion Pharmaceuticals May Be Losing Ground To Its Peers
Apr 28
RXRX: Later Launch And Higher Costs Will Set Up Cleaner Upside
Analysts have trimmed their price target on Recursion Pharmaceuticals to $6 from $7, citing updated operating expense and share count assumptions, as well as a later expected launch timeline for REC-617. Analyst Commentary Bullish analysts point out that the recent cut to a US$6 price target still reflects confidence in Recursion Pharmaceuticals reaching key development milestones over time, even with updated expense forecasts and a later expected REC-617 launch.Recursion Pharmaceuticals! WTH is going on?
I was very pessimistic about RXRX! I am now extremely optimistic and here’s why!RXRX: Later Launch Assumptions Will Set Up Cleaner Long Term Upside
Analysts recently trimmed their 12 month price target for Recursion Pharmaceuticals to $6 from $7, citing revised operating expense assumptions, a higher share count, and a later expected launch timing for REC-617. Analyst Commentary Recent commentary around Recursion Pharmaceuticals has focused on updated assumptions for operating expenses, a higher share count, and a later expected launch for REC-617.RXRX: Later Launch And Cleaner Model Assumptions Will Support Long Term Upside
Analysts have lowered their price target on Recursion Pharmaceuticals to $6 from $7, citing updated operating expense assumptions, a revised share count, and a later expected launch timing for REC-617. Analyst Commentary While the latest research includes a lower price target, recent commentary still highlights areas where bullish analysts see room for Recursion Pharmaceuticals to execute and create value over time.RXRX: FAP Data And Cautious Outlook Will Support Long Term Thesis
Analysts have trimmed their price target for Recursion Pharmaceuticals to $6 from $7, citing revised estimates, updated operating expense and share count assumptions, and a later expected launch for REC-617. Analyst Commentary Recent commentary points to a more cautious tone on Recursion Pharmaceuticals, with the latest price target reset to reflect updated expense planning, share count expectations, and a later potential launch for REC-617.Recursion Pharmaceuticals! WTH is going on?
As I see what RXRX did in the 4th quarter I now believe they will be the Palantir of biotechnology one day! Najat Khan the new CEO will lead this company out of the hole created by the former CEO into greatness!
RXRX: FAP Trial Success Will Support Future Margin Expansion Potential
Analysts have maintained their $7.00 price target on Recursion Pharmaceuticals, citing broadly consistent long term assumptions and only minor adjustments to the discount rate, profit margin outlook, and future P/E multiple. What's in the News Recursion reported positive Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an allosteric MEK1/2 inhibitor being studied for familial adenomatous polyposis, with REC-4881 4 mg QD linked to rapid clinical activity in the trial population (Key Developments).RXRX: Positive FAP Trial Data Will Support Stronger Long Term Thesis
Analysts have raised their price target on Recursion Pharmaceuticals to US$11.00, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E as the key drivers of the change. What's in the News Recursion reported positive Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis.RXRX: Positive FAP Trial Results Will Support Future Margin Expansion
Analysts have modestly adjusted their price target on Recursion Pharmaceuticals, citing updated assumptions around the discount rate, long-term revenue growth, profit margin, and future P/E. Together, these revisions lead to a refined fair value estimate of US$7.00 per share.RXRX: Positive FAP Trial Data Will Support Stronger Long Term Thesis
Analysts have lifted their fair value estimate for Recursion Pharmaceuticals from US$10.00 to US$11.00, citing updated assumptions around revenue growth, profit margin, and future P/E levels as key drivers of the new target. What's in the News Recursion reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (Key Developments).RXRX: Positive TUPELO Data Will Drive Future AI-Enabled Margin Expansion
Analysts have raised their price target on Recursion Pharmaceuticals by approximately 10 percent to around 7.00 dollars per share, citing a modestly higher fair value estimate despite tempered revenue growth assumptions. What's in the News Announced positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, with 75 percent of evaluable patients showing reduced total polyp burden and a 43 percent median reduction after 12 weeks of treatment (Key Developments).RXRX: New CEO Appointment Will Spark Stronger Margins And AI-Driven Momentum
Analysts have modestly raised their price target for Recursion Pharmaceuticals from $6.30 to $6.33 per share. They cite improved forecasted revenue growth and higher profit margins as key drivers behind the update.RXRX: Leadership Change Will Drive Future Opportunity Amid Accelerating Revenue Outlook
Analysts have lowered their price target for Recursion Pharmaceuticals from $6.47 to $6.30, citing adjustments in projected discount rates and profit margins despite stronger expected revenue growth. What's in the News Dr. Najat Khan has been appointed as Chief Executive Officer of Recursion Pharmaceuticals, effective January 1, 2026 (Key Developments).Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
Nov 07Recursion: FDA To Replace Animal Testing With AI? - A Small But Necessary Win
Apr 11Recursion: A Look At Near-Term Phase 1b And Phase 2 Catalysts
Mar 27
REC-617 And REC-994 Trials Will Drive Future AI-Driven Drug Discovery Success
Successful clinical trials and expanded pipeline indicate promising future revenue growth and earnings from potential drug market entries.Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns
Mar 12This Just In: Analysts Are Boosting Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Outlook for This Year
Mar 02Recursion Pharmaceuticals Needs A Clinical Breakthrough To Pique Interest
Feb 14Recursion: Investors Will Need To Be Patient
Jan 10Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Dec 25Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245
Dec 09Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline
Nov 20Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week
Nov 10Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk
Nov 08Recursion: AI Is Only As Good As The Data
Sep 11Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$560m |
| Dec 31 2025 | n/a | n/a | -US$645m |
| Sep 30 2025 | n/a | n/a | -US$716m |
| Jun 30 2025 | n/a | n/a | -US$649m |
| Mar 31 2025 | n/a | n/a | -US$575m |
| Dec 31 2024 | US$9m | US$285k | -US$464m |
Compensación vs. Mercado: La compensación total de Najat($USD9.19M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.48M).
Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Najat con los resultados de la empresa.
CEO
Najat Khan (41 yo)
less than a year
Permanencia
US$9,194,804
Compensación
Dr. Najat Khan, Ph D is Chief Executive Officer and President of Recursion Pharmaceuticals, Inc. January 1, 2026. She was Chief R&D Officer and Chief Commercial Officer of Recursion Pharmaceuticals, Inc. f...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 12.5yrs | US$8.50m | 1.04% $ 18.4m | |
| CEO, President & Director | less than a year | US$9.19m | 0.0077% $ 137.2k | |
| CFO & President of Recursion UK | 1.5yrs | US$8.59m | 0.049% $ 867.4k | |
| Advisor | 2.9yrs | US$1.93m | 0.014% $ 251.2k | |
| Chief Operating Officer | 1.5yrs | sin datos | sin datos | |
| Chief Technology Officer | 6.3yrs | sin datos | sin datos | |
| Chief Scientific Officer | 1.5yrs | sin datos | 0.072% $ 1.3m | |
| Chief Legal Officer & Corporate Secretary | 2.6yrs | sin datos | sin datos | |
| Chief Communications Officer | no data | sin datos | sin datos | |
| Chief People and Impact Officer | 1.5yrs | sin datos | sin datos | |
| Chief Business Officer | 1.5yrs | sin datos | sin datos | |
| Senior Vice President of Clinical Development & Data Science | less than a year | sin datos | sin datos |
1.5yrs
Permanencia media
45yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de RXRX no se considera experimentado ( 1.5 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 12.5yrs | US$8.50m | 1.04% $ 18.4m | |
| CEO, President & Director | 2.1yrs | US$9.19m | 0.0077% $ 137.2k | |
| Member of Business Advisory Panel | 11.5yrs | sin datos | sin datos | |
| Member of Business Advisory Panel | 11.9yrs | sin datos | sin datos | |
| Chairman of Therapeutics Advisory Board | 4.8yrs | sin datos | sin datos | |
| Vice-Chairman & Lead Independent Director | 6.2yrs | US$316.48k | 0.0098% $ 174.3k | |
| Director | less than a year | US$296.73k | 0.61% $ 10.8m | |
| Independent Director | 13.3yrs | US$294.98k | 1.18% $ 20.9m | |
| Member of Scientific and Technical Advisory Board | 12.1yrs | sin datos | sin datos | |
| Member of Scientific & Technical Advisory Board | 12.1yrs | sin datos | sin datos | |
| Independent Director | 9.7yrs | US$304.23k | 0.024% $ 422.0k | |
| Independent Director | 1.2yrs | sin datos | sin datos |
10.6yrs
Permanencia media
57.5yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de RXRX son experimentados ( 10.6 años antigüedad media).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/06 01:51 |
| Precio de las acciones al final del día | 2026/05/06 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Recursion Pharmaceuticals, Inc. está cubierta por 13 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Gal Munda | Berenberg |
| Gaurav Goparaju | Berenberg |
| Alec Stranahan | BofA Global Research |